Advaxis (NASDAQ:ADXS) posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.06, Yahoo Finance reports. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million.
Shares of Advaxis stock traded down $0.01 on Thursday, reaching $1.75. The stock had a trading volume of 624,139 shares, compared to its average volume of 1,123,157. Advaxis has a 1 year low of $1.51 and a 1 year high of $9.55. The company has a market cap of $85.27, a price-to-earnings ratio of -0.76 and a beta of 1.19.
Several brokerages have recently commented on ADXS. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the company a “buy” rating in a report on Friday, December 22nd. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, December 27th.
Advaxis Company Profile
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.